Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) reachead $65.80 at the closing of the latest trading day, reflecting a +1.83% change compared to its last close.
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Viking recently announced the results of an early-stage clinical trial for VK0214.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Where Will Viking Therapeutics Be in 5 Years?
We could be witnessing the birth of a major player in the biotech industry.
The Ultimate Biotech Stock to Buy With $100 Right Now
This company is operating in one of today's hottest markets.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD
Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $64.96, denoting a +1.33% change from the preceding trading day.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $64.11, marking a -0.9% move from the previous day.
